Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor in T2DM and NAFLD
NCT03459079Phase 2Completed
- Sponsor
- University of Florida
- Start
- Aug 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lanifibranor in non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), sponsored by University of Florida. Started Aug 2018; status: completed.
02
Drugs
lanifibranor
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03459079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459079.